| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADCY5 |
| Uniprot No | O95622 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1261aa |
| 氨基酸序列 | MSGSKSVSPPGYAAQKTAAPAPRGGPEHRSAWGEADSRANGYPHAPGGSARGSTKKPGGAVTPQQQQRLASRWRSDDDDDPPLSGDDPLAGGFGFSFRSKSAWQERGGDDCGRGSRRQRRGAASGGSTRAPPAGGGGGSAAAAASAGGTEVRPRSVEVGLEERRGKGRAADELEAGAVEGGEGSGDGGSSADSGSGAGPGAVLSLGACCLALLQIFRSKKFPSDKLERLYQRYFFRLNQSSLTMLMAVLVLVCLVMLAFHAARPPLQLPYLAVLAAAVGVILIMAVLCNRAAFHQDHMGLACYALIAVVLAVQVVGLLLPQPRSASEGIWWTVFFIYTIYTLLPVRMRAAVLSGVLLSALHLAIALRTNAQDQFLLKQLVSNVLIFSCTNIVGVCTHYPAEVSQRQAFQETRECIQARLHSQRENQQQERLLLSVLPRHVAMEMKADINAKQEDMMFHKIYIQKHDNVSILFADIEGFTSLASQCTAQELVMTLNELFARFDKLAAENHCLRIKILGDCYYCVSGLPEARADHAHCCVEMGMDMIEAISLVREVTGVNVNMRVGIHSGRVHCGVLGLRKWQFDVWSNDVTLANHMEAGGKAGRIHITKATLNYLNGDYEVEPGCGGERNAYLKEHSIETFLILRCTQKRKEEKAMIAKMNRQRTNSIGHNPPHWGAERPFYNHLGGNQVSKEMKRMGFEDPKDKNAQESANPEDEVDEFLGRAIDARSIDRLRSEHVRKFLLTFREPDLEKKYSKQVDDRFGAYVACASLVFLFICFVQITIVPHSIFMLSFYLTCSLLLTLVVFVSVIYSCVKLFPSPLQTLSRKIVRSKMNSTLVGVFTITLVFLAAFVNMFTCNSRDLLGCLAQEHNISASQVNACHVAESAVNYSLGDEQGFCGSPWPNCNFPEYFTYSVLLSLLACSVFLQISCIGKLVLMLAIELIYVLIVEVPGVTLFDNADLLVTANAIDFFNNGTSQCPEHATKVALKVVTPIIISVFVLALYLHAQQVESTARLDFLWKLQATEEKEEMEELQAYNRRLLHNILPKDVAAHFLARERRNDELYYQSCECVAVMFASIANFSEFYVELEANNEGVECLRLLNEIIADFDEIISEDRFRQLEKIKTIGSTYMAASGLNDSTYDKVGKTHIKALADFAMKLMDQMKYINEHSFNNFQMKIGLNIGPVVAGVIGARKPQYDIWGNTVNVASRMDSTGVPDRIQVTTDMYQVLAANTYQLECRGVVKVKGKGEMMTYFLNGGPPLS |
| 预测分子量 | 138,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADCY5重组蛋白的3篇示例参考文献(注：以下为模拟文献，实际引用请核实真实来源)：
---
1. **文献名称**: "Recombinant Human ADCY5: Expression, Purification, and Functional Characterization"
**作者**: Smith, J.R., et al.
**摘要**: 本研究报道了人源ADCY5重组蛋白在大肠杆菌中的高效表达及纯化方法。通过体外酶活实验证实，纯化的ADCY5蛋白具有依赖G蛋白的cAMP合成活性，并揭示了其动力学参数，为后续药物筛选提供了基础。
2. **文献名称**: "Structural Insights into ADCY5 Activation Mechanism by Cryo-EM"
**作者**: Chen, L., et al.
**摘要**: 利用冷冻电镜技术解析了ADCY5重组蛋白与Gsα亚基复合物的高分辨率结构，揭示了ADCY5在G蛋白偶联信号中的构象变化机制，为理解其生理功能及突变相关疾病的分子机制提供了结构基础。
3. **文献名称**: "ADCY5 Mutations Alter cAMP Signaling in Hyperkinetic Movement Disorders"
**作者**: Johnson, M.T., et al.
**摘要**: 通过表达携带致病突变(如R418W)的ADCY5重组蛋白，发现突变体导致cAMP异常累积，证实ADCY5功能增益性突变与运动障碍疾病的关联，为靶向治疗策略开发提供了依据。
---
**说明**：以上文献为示例，实际研究中请通过PubMed或Web of Science等数据库检索真实发表的论文。如需具体文献协助，请提供更详细的研究方向或关键词。
Adenylyl cyclase 5 (ADCY5), a member of the adenylate cyclase family, is a membrane-bound enzyme that catalyzes the conversion of ATP to cyclic AMP (cAMP), a critical secondary messenger in cellular signaling. As one of nine transmembrane adenylyl cyclase isoforms in mammals, ADCY5 is predominantly expressed in the brain, skeletal muscle, and heart, where it regulates processes like neurotransmission, muscle contraction, and cardiac function. Its activity is tightly controlled by G protein-coupled receptors (GPCRs) through stimulatory (Gαs) or inhibitory (Gαi) subunits.
Recombinant ADCY5 protein, produced via heterologous expression systems (e.g., HEK293 or insect cells), enables structural and functional studies of this enzyme. Researchers use it to investigate its regulatory mechanisms, including interactions with G proteins, calcium/calmodulin, and pharmacological modulators. Notably, ADCY5 has gained attention due to its association with neurological disorders. Germline mutations in the ADCY5 gene cause autosomal dominant dyskinesias, characterized by early-onset movement disorders, while somatic mutations link to cancer progression.
The recombinant protein serves as a tool for drug screening, particularly for neurological and cardiovascular therapeutics, and for studying mutation-induced hyperactivity or hypoactivity observed in disease models. Its 3D structure, partially resolved through cryo-EM, provides insights into catalysis and regulation. Current research focuses on ADCY5's role in cAMP compartmentalization and its tissue-specific signaling outcomes, highlighting its potential as a therapeutic target for movement disorders and other cAMP-related pathologies.
×
